Company Filing History:
Years Active: 1984-2015
Title: The Innovative Contributions of Ellis L Reinherz
Introduction
Ellis L Reinherz, based in Lincoln, MA, is a prominent inventor known for his significant contributions in the field of immunology and biotechnology. With a portfolio of 15 patents, he has made substantial advancements that have a lasting impact on medical research and applications.
Latest Patents
Among his latest patents, Reinherz focuses on two notable innovations. The first is the "Identification of Conserved Peptide Blocks in Homologous Polypeptides," which provides methods for identifying conserved peptide blocks in multiple homologous polypeptides. This work has critical implications for selecting conserved peptides in variable viral polypeptides intended for immunogenic compositions. The second patent is an "Oligonucleotide Array for Tissue Typing," which features oligonucleotide-based microarrays for high-resolution tissue typing, particularly useful in diagnostic evaluations and assessing donor/recipient transplant compatibility.
Career Highlights
Reinherz has had an illustrious career, working at esteemed institutions such as the Dana-Farber Cancer Institute and the Sidney Farber Cancer Institute. His innovative research and development efforts have helped advance the understanding and treatment of various diseases, particularly in the realm of cancer and immunotherapy.
Collaborations
Throughout his career, Ellis L Reinherz has collaborated with various professionals, including notable coworkers Peter Sayre and Hsiu-Ching Chang. These collaborations have fostered a creative environment conducive to innovation, producing groundbreaking methodologies and applications in medical science.
Conclusion
Ellis L Reinherz’s contributions to the fields of immunology and biotechnology are notable and impactful. With 15 patents to his name, his work continues to inspire and drive advances in medical research, highlighting the importance of collaboration and innovation in addressing complex scientific challenges.